Here’s what you should know.
1. The therapy consisted of Exelixis’ Cotellic combined with Roche’s Tecentriq.
2. The combination was safe, but ineffective.
3. The failure caused Exelixis stock to slide to a new 11-month low, hitting $18.56 May 10.
4. For Roche, this is the latest of several failed therapies, which is dissuading investors.
More articles on gastroenterology:
Carl King takes the helm of NueHealth Holdings: 6 things to know
Dr. Julian Cameron leverages Less Exposure Surgery tech at Florida ASC — 4 highlights
Coding tip of the day: Avoid coding burnout with simple strategies
